Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan

Psychiatry Research

Volumn 186, Issue 2-3, 2011, Pages 326-332

  Okuno, Kanae ^a   Yoshimura, Reiji ^a   Ueda, Nobuhisa ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Hori, Hikaru ^a   Hayashi, Kenji ^a   Katsuki, Asuka ^a   Chen, Hsin I ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

BDNF; Biological markers; MHPG; Personality trait; Psychological job stress

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR;

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD LEVEL; BRAIN DERIVED NEUROTROPHIC FACTOR BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; JAPAN; JOB STRESS; MALE; MENTAL STRESS; PERSONALITY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PUBLISHING; QUESTIONNAIRE; SOCIAL ADAPTATION; SOCIAL ADAPTATION SELF EVALUATION SCALE; STRESS AND AROUSAL CHECK LIST;

BRAIN-DERIVED NEUROTROPHIC FACTOR; EMPLOYMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JAPAN; MALE; METHOXYHYDROXYPHENYLGLYCOL; PERSONALITY; PSYCHIATRIC STATUS RATING SCALES; PUBLISHING; SEX FACTORS; SOCIAL ADJUSTMENT; STRESS, PSYCHOLOGICAL;

EID: 79952364467     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.07.023     Document Type: Article

References (65)

1. Bosc M., Dubini A., Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European Neuropsychopharmacology 1997, 7:57-70.
2. Brunoni A.R., Lopes M., Gregni F.A. Systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. International Journal of Neuropharmacology 2008, 11:1169-1180.
3. Calabrese F., Molteni R., Maj P.F., Cattaneo A., Gennarelli M., Racagni G., Riva M.A. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32:2351-2359.
4. Charney D.S., Redmond D.E. Neurobiological mechanisms in human anxiety. Evidence supporting central noradrenergic hyperactivity. Neuropharmacology 1983, 22:1531-1536.
5. Chen M.J., Nguyen T.V., Pike C.J., Russo-Neustadt A.A. Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal 2006, 19:114-128.
6. Cohen S., Sherrod D.R., Clark M.S. Social skills and the stress-protective role of social support. Journal of Personality and Social Psychology 1986, 50:963-973.
7. Conull J.T., Middleton H.C., Robbins T.W., Sahakian B.J. Clonidine and diazepam have differential effects on tests of attention and learning. Psychopharmacology 1995, 120:322-332.
8. Costa P.T., McCrae R.R. Revised NEO Personality Inventory and NEO Five-factor Inventory, Professional Manual 1992, Psychological Assessment Resources, Odessa, FL.
9. Dubini A., Bosc M., Polin V. Do noradrenaline and serotonin differentially affect social motivation and behavior ?. European Neuropsychopharmacology 1997, 7:49-55.
10. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related disorders. Biological Psychiatry 2006, 59:1116-1127.
11. Duman R.S., Malberg J., Nakagawa S., D' Sa C. Neuronal plasticity and survival in mood disorders. Biological Psychiatry 2000, 48:732-739.
12. Durman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Archives of General Psychiatry 1997, 54:597-605.
13. Figurov A., Pozzo-Miller L.D., Olafsson P., Wang T., Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996, 381:706-709.
14. Fukuda M., Hata A., Niwa S., Hiramatsu K., Honda H., Nakagome K., Iwanami A. Plasma vanillymandelic acid level as an index of psychological stress response in normal subjects. Psychiatry Research 1996, 63:7-16.
15. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. European Archives of Psychiatry and Clinical Neuroscience 2005, 255:381-386.
16. Goto M., Ueda N., Yoshimura R., Shingo K., Kyoko K., Yamada Y., Higuchi T., Nakamura J. Reliability and validity of the Japanese version of the Social Adaptation Self-evaluating Scale (SASS). Seishinigaku 2005, 47:483-489. (in Japanese).
17. Halbrugge T., Gerhardt T., Ludwig J., Heidbreder E., Graefe K.H. Assay of catecholamines and dihydroxyphenylethyleneglycol in human plasma and its application in orthostasis and mental stress. Life Science 1988, 43:19-26.
18. Harker L.A., Roskos L.K., Marzec U.M., Carter R.A., Cherry J.K., Sundell B., Cheung E.N., Terry D., Sheridan W. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000, 95:2514-2522.
19. Januszewicz W., Sznajderman M., Wocial B., Feltynowski T., Klonowicz T. The effect of mental stress on catecholamines, their metabolites, and plasma renin activity in patients with essential hypertension and healthy subjects. Clinical Science 1979, 57:229-231.
20. Jonsson E.G., Saetre P., Edman-Ahlbom B., Sillen A., Gunnar A., Andreou D., Agartz I., Sedvall G., Hall H., Terenius L. Brain-derived neurotrophic factor gene variation influences cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol concentrations in healthy volunteers. Journal of Neural Transmission 2008, 115:1695-1699.
21. Juric D.M., Miklic S., Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Research 2006, 1108:54-62.
22. Karege F., Bovier P.H., Gaillard J.M., Tissort R. Plasma MHPG and AMDP depression relations, evolution and drug effect in a follow up study of depressed patients. Human Psychopharmacology 1991, 6:11-17.
23. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 2002, 109:143-148.
24. Kim Y.-K., Lee H.-P., Won S.-D., Park E.-Y., Lee H.-Y., Lee B.-H., Lee S.-W., Yoon D., Han C., Kim D.-J., Choi S.-H. Low plasma BDNF is associated with suicidal behavior in major depression. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:78-85.
25. Kobayashi K., Shimizu E., Hashimoto K., Mitsumori M., Koike K., Okamura N., Matsuzawa D., Zhang L., Kumakiri C., Nakazato M., Komatsu N., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavior therapy. Progress in Neuropsychopharmacology and Biological Psychiatry 2005, 29:658-663.
26. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacological Review 1985, 37:333-364.
27. Korte M., Carrol P., Wolf E., Brem G., Thoenen H., Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proceedings of National Academy of Sciences of the United State of America 1995, 92:8856-8860.
28. Kumashiro M. How many ergonomics interventions do we have in the field of occupational stress?. Sangyo Eiseigaku Zasshi 2002, 44:87-94. (in Japanese).
29. Lang U.E., Hellweg R., Gallinat J. BDNF concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004, 29:795-798.
30. Lang U.E., Hellweg R., Kalus P., Bajbouj M., Lenzen K.P., Sander T., Kunz D., Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology 2005, 180:95-99.
31. Li G.Y., Ueki H., Kawashima T., Sugataka K., Muraoka T., Yamada S. Involvement of the noradrenergic system in performance on a continuous task requiring effortful attention. Neuropsychobiology 2004, 50:336-340.
32. Lommatzsch M., Zinger D., Schuhbaeck K., Scuhbaek K., Schloetcke K., Zinger C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiological Aging 2005, 26:115-123.
33. Maas J.W. Clinical and biochemical heterogeneity of depressive disorder. Annals of Internal Medicine 1978, 88:556-563.
34. Maas J.W., Hattox S.E., Greene N.M., Landis D.H. 3-Methoxy-4-hydroxyphenethyleneglycol production by human brain in vivo. Science 1979, 205:1025-1027.
35. Mackay C., Cox T., Burrows G., Lazzerini T. An inventory for the measurement of self-reported stress and arousal. British Journal of Social Clinical Psychology 1978, 17:283-284.
36. Marano C.M., Phatak P., Vemulapalli U.R., Sasan A., Nalbandyran M.R., Ramanujan S., Soekadar S., Demosthenous M., Regenold T.W. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. Journal of Clinical Psychiatry 2007, 68:512-517.
37. Mason S.T., Fiber H.C. Current concepts I Anxiety: the locus coeruleus disconnection. Life Science 1979, 25:2141-2147.
38. McAllister A.K., Katz L.C., Lo D.C. Neurotrophins and synaptic plasticity. Annual Revews of Neuroscience 1999, 22:295-318.
39. Mitchel D.A., Lambert G., Secher N.H., Raven P.B., Van Lieshout J., Esler M.D. Jugular venous overflow of noradrenaline from the brain: a neurochemical indicator of cerebrovascular sympathetic nerve activity in humans. Journal of Psychiology 2009, 587.
40. Mitoma M., Yoshimura R., Sugita A., Umene W., Hori H., Nakano H., Ueda N., Nakamura J. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. Progress in Neuropsychopharmacology and Biological Psychiatry 2008, 32:679-685.
41. Mizuki Y., Kajimura N., Kai S., Suetsugi M., Ushijima I., Yamada M. Differential response to mental stress in high and low anxious normal humans assessed by frontal middle theta activity. International Journal of Psychophysiology 1992, 12:169-178.
42. Nagaoka S., Iwamoto N., Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and thier correlations with clinical response to haloperidol treatment. Biological Psychiatry 1997, 41:857-864.
43. Noh J.S., Kim E.Y., Kang J.S., Kim H.R., Oh Y.J., Gwag B.J. Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Experimental Neurology 1999, 159:217-224.
44. Paddock J.R., Nowicki S. Paralanguage and the interpersonal impact of dysphoria: it's not what you say but how you say it. Social Behavior and Personality 1986, 14:29-44.
45. Podusto J.F., Curran G.L. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Molecular Brain Research 1996, 36:280-286.
46. Redmond D.E., Huang Y.H. Current concepts II New evidence for a locus ceruleus-norepinephrine connection with anxiety. Life Science 1979, 25:2149-2162.
47. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives of General Psychiatry 2000, 57:925-935.
48. Sen S., Nesse R.M., Stoltenberg S.F., Li S., Gleiberman L., Chakravarti A., Weder A.B., Burmeister M. A BDNF coding varient is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003, 28:377-401.
49. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008, 64:527-532.
50. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Barker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(supplement 20):22-33. quiz 34-57.
51. Shelton R.C. Cellular mechanisms in the vulnerability to depression and response to antidepressants. Psychiatric Clinics of North America 2000, 23:713-729.
52. Shildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry 1965, 122:509-522.
53. Shimizu E., Hashimoto K., Okuma N., Koike K., Komatsu N., Kumakiri C., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003, 54:70-75.
54. Shinkai K., Yoshimura R., Ueda N., Okamoto K., Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. Journal of Clinical Psychopharmacology 2004, 24:11-17.
55. Southwick S., Davis M., Horner B., Cahill L., Morgan C.A., Gold P.E., Bremner J.D., Charney D.C. Relationship of enhanced norepinephrine activity during memory consolidation to enhanced long-term memory in humans. American Journal of Psychiatry 2002, 159:1420-1422.
56. Thoenen H. Neurotrophins and neural plasticity. Science 1995, 270:593-598.
57. Tse W.S., Bond A.J. Consequences of displaying abnormal social behavior and reduction of social reinforcement. Journal of Affective Dirorders 2003, 75:49-58.
58. Ueda N., Yoshimura R., Shinkai K., Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002, 35:175-181.
59. Umene-Nakano W., Yoshimura R., Ueda N., Suzuki A., Ikenouchi-Sugita A., Hori H., Otani K., Nakamura J. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. Journal of Psychopharmacology 2010, 24:1764-1771.
60. Yoshimura R., Nakamura J., Ueda N., Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. International Clinical Psychopharmacology 2000, 15:175-180.
61. Yoshimura R., Nakamura J., Shinkai K., Ueda N. Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Progress in Neuropsychopharmacology and Biological Psychiatry 2004, 28:611-616.
62. Yoshimura R., Nakano Y., Hori H., Ikenouchi A., Ueda N., Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Human Psychopharmacology 2006, 21:433-438.
63. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., Nakamura J. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:1034-1037.
64. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., Shinkai T., Nakamura J. Treatment with risperidone for 4weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:1072-1077.
65. Yukimasa T., Yoshimura R., Tamagawa A., Uozumi A., Shinkai K., Ueda N., Tsuji S., Nakamura J. High-frequency repetitive transcranial stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 2006, 39:52-59.